Investor Presentation Q1 2023
21
Investor presentation
First three months of 2023
Sales growth of 25%, driven by the GLP-1 portfolio for diabetes
and obesity treatment
Novo NordiskⓇ
Novo Nordisk reported quarterly sales
DKK
billion
60
by therapy
Reported sales
CAGR1: 9.6%
50
50
Reported sales for the first
quarter of 2023
Rare Other
Rare endocrine rare
blood disorders disease
disorders
Reported sales and growth breakdown for
the first quarter of 2023
Therapy
Sales
(mDKK)
Growth
Share of
growth
Total GLP-12
26,811
50%
84%
Long-acting insulin³
4,133
-14%
-7%
40
40
-6.1%1
0%
6% 2%
Premix insulin+
2,776
-7%
-2%
Fast-acting insulin
4,488
-9%
-4%
Obesity
Human insulin
-2.7%¹
care
15%
2,012
-11%
-3%
30
Total insulin
13,409
-11%
-15%
20
20
1.8%1
11.4 %1
Other Diabetes care
729
-21%
-2%
Total Diabetes care
40,949
21%
67%
Obesity care?
7,842
124%
41%
10
77%
Diabetes care
Diabetes and Obesity care
Rare blood disorders8
48,791
31%
108%
3,049
-3%
-1%
0
Q1
Other rare disease
2013
Rare endocrine disorders
Rare blood disorders
Q1
2023
Rare endocrine disorders⁹
Other Rare disease 10
Rare disease
1,128
-38%
-7%
399
-12%
0%
4,576
-16%
-8%
Diabetes and Obesity care
Sales of DKK 53.0 billion
(+27%)
Total
53,367
25%
100%
1 CAGR for 10-year period; 2 Comprises Victoza®, Ozempic®, Rybelsus®; 3 Comprises TresibaⓇ, XultophyⓇ and Levemir®; 4 Comprises RyzodegⓇ and Novo MixⓇ; 5 Comprises FiaspⓇ and NovoRapidⓇ: 6 Primarily NovonormⓇ, needles and GlucaGen® HypoKitⓇ;
7 Comprises SaxendaⓇ and Wegovy®: 8 Comprises NovoSeven®, Novo Eight®, NovoThirteen®, Refixia®, and EsperoctⓇ: 9 Comprises Norditropin and Macrilen TM; 10 Primarily Vagifem® and ActivelleⓇ
Note: Sales numbers are reported in Danish kroner; Growth is at constant exchange rate, except for total sales growth of 26%; Refixia® and NovoThirteenⓇ are launched as RebinynⓇ and TRETTENⓇ, respectively, in North America.View entire presentation